The urgent need to develop an effective vaccine to
provide individuals and populations worldwide with immunity against
the COVID-19 disease caused by the novel coronavirus, SARS-CoV-2,
has led several biotechnology companies to leverage messenger RNA
(mRNA) technology and take a novel approach to vaccine
development.
As the COVID-19 pandemic continues to unfold, there are a
multitude of biotechnology companies, governments and research
institutions concentrating their efforts on developing a
prophylactic vaccine against the novel coronavirus known as
SARS-CoV-2. Many conventional vaccine development approaches are
problematic because they involve prolonged lead times of between 2
to 5 years and require significant capital investment, making them
poorly-adapted to responding to a rapidly spreading pathogen. By
contrast, mRNA-based vaccines can be developed, clinically trialled
and scaled-up into production and distribution relatively quickly
– with the possibility of